Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.44 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.42 |
| ▸ | PTGES | O14684 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | OGG1 | O15527 | 1/20 | 0.41 |
| ▸ | KLK7 | P49862 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14122553 | 1.00 | ALDH1A1 (0.49) | ALDH1A1CYP4F2CYP4A11MEP1BTSHR | |
| SCHEMBL14121968 | 1.00 | ALDH1A1 (0.49) | ALDH1A1CYP4F2CYP4A11MEP1BTSHR | |
| SCHEMBL14157560 | 0.88 | ALDH1A1 (0.44) | ALDH1A1TSHRALDH2MAPT | |
| SCHEMBL14157559 | 0.88 | ALDH1A1 (0.44) | ALDH1A1TSHRALDH2MAPT | |
| SCHEMBL2174618 | 0.86 | ALDH1A1 (0.47) | ALDH1A1TSHRALDH2LMNAL3MBTL1 | |
| SCHEMBL14122189 | 0.86 | L3MBTL1 (0.51) | ALDH1A1TSHRALDH2LMNAL3MBTL1 | |
| SCHEMBL14122191 | 0.86 | L3MBTL1 (0.51) | ALDH1A1TSHRALDH2LMNAL3MBTL1 | |
| SCHEMBL7228518 | 0.86 | ALDH1A1 (0.47) | ALDH1A1TSHRALDH2LMNAL3MBTL1 | |
| SCHEMBL14122286 | 0.85 | ALDH1A1 (0.50) | ALDH1A1CYP4F2CYP4A11MEP1BPTGES | |
| SCHEMBL13384052 | 0.85 | L3MBTL1 (0.43) | ALDH1A1CYP4F2CYP4A11MEP1BTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240009169-A9 | PPARG Modulators for the Treatment of Osteoporosis | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2024-01-11 | — | — | US | disclosed |
| US-20230072933-A1 | PPARG Modulators for the Treatment of Osteoporosis | SCRIPPS RESEARCH INST (US) | 2023-03-09 | — | — | US | disclosed |
| US-20230072933-A1 | PPARG Modulators for the Treatment of Osteoporosis | SCRIPPS RESEARCH INST (US) | 2023-03-09 | — | — | US | disclosed |
| US-10744117-B2 | PPARG modulators for the treatment of osteoporosis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-08-18 | — | — | US | disclosed |
| US-10744117-B2 | PPARG modulators for the treatment of osteoporosis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-08-18 | — | — | US | disclosed |
| US-20180369196-A1 | PPARG Modulators for the Treatment of Osteoporosis | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2018-12-27 | — | — | US | disclosed |
| US-10016394-B2 | PPARG modulators for treatment of osteoporosis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-07-10 | — | — | US | disclosed |
| US-10016394-B2 | PPARG modulators for treatment of osteoporosis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-07-10 | — | — | US | disclosed |
| US-10016394-B2 | PPARG modulators for treatment of osteoporosis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170035730-A1 | PPARG MODULATORS FOR TREATMENT OF OSTEOPOROSIS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2017-02-09 | — | — | US | disclosed |
| US-9051265-B2 | N-benzylindole modulators of PPARG | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-06-09 | — | — | US | disclosed |
| US-20140288090-A1 | N-ARYLYLMETHYLINDAZOLE MODULATORS OF PPARG | SCRIPPS RESEARCH INSTITUTE, THE | 2014-09-25 | — | — | US | disclosed |
| US-20140249196-A1 | N-BENZYLBENZIMIDAZOLE MODULATORS OF PPARG | SCRIPPS RESEARCH INSTITUTE, THE | 2014-09-04 | — | — | US | disclosed |
| US-20140249196-A1 | N-BENZYLBENZIMIDAZOLE MODULATORS OF PPARG | SCRIPPS RESEARCH INSTITUTE, THE | 2014-09-04 | — | — | US | disclosed |
| US-20140249196-A1 | N-BENZYLBENZIMIDAZOLE MODULATORS OF PPARG | SCRIPPS RESEARCH INSTITUTE, THE | 2014-09-04 | — | — | US | disclosed |
| WO-2013078237-A1 | N-ARYLYLMETHYLINDAZOLE MODULATORS OF PPARG | RIPKA AMY S (US) | 2013-05-30 | — | — | WO | disclosed |
| WO-2012170561-A1 | N-BENZYLINDOLE MODULATORS OF PPARG | THE SCRIPPS RESEARCH INSTITUTE (T.S.R.I.) (US) | 2012-12-13 | — | — | WO | disclosed |
| US-20120309769-A1 | N-BENZYLINDOLE MODULATORS OF PPARG | SCRIPPS RESEARCH INSTITUTE, THE (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120309769-A1 | N-BENZYLINDOLE MODULATORS OF PPARG | SCRIPPS RESEARCH INSTITUTE, THE (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120309769-A1 | N-BENZYLINDOLE MODULATORS OF PPARG | SCRIPPS RESEARCH INSTITUTE, THE (US) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170035730-A1 | PPARG MODULATORS FOR TREATMENT OF OSTEOPOROSIS | PPARG, PPARA, PPARD | ALDH1A1 4434/4885CYP4F2 2899/4885CYP4A11 957/4885 |
| US-10016394-B2 | PPARG modulators for treatment of osteoporosis | PPARG, PPARA, PPARD | ALDH1A1 4434/4885CYP4F2 2899/4885CYP4A11 957/4885 |
| US-20120309769-A1 | N-BENZYLINDOLE MODULATORS OF PPARG | PPARG, CDK5R1, CDK5 | ALDH1A1 4172/4885CYP4F2 3601/4885CYP4A11 1516/4885 |
| US-20140288090-A1 | N-ARYLYLMETHYLINDAZOLE MODULATORS OF PPARG | CDK5, CDK5R1, PPARG | ALDH1A1 2627/4885CYP4F2 3375/4885CYP4A11 1058/4885 |
| US-20140249196-A1 | N-BENZYLBENZIMIDAZOLE MODULATORS OF PPARG | PPARG, CDK5, CDK5R1 | ALDH1A1 3299/4885CYP4F2 3748/4885CYP4A11 1957/4885 |
| US-20230072933-A1 | PPARG Modulators for the Treatment of Osteoporosis | PPARG, PPARA, PPARD | ALDH1A1 4575/4885CYP4F2 2621/4885CYP4A11 729/4885 |
| US-20180369196-A1 | PPARG Modulators for the Treatment of Osteoporosis | PPARG, PPARA, PPARD | ALDH1A1 4575/4885CYP4F2 2621/4885CYP4A11 729/4885 |
| US-10744117-B2 | PPARG modulators for the treatment of osteoporosis | PPARG, PPARA, PPARD | ALDH1A1 4575/4885CYP4F2 2621/4885CYP4A11 729/4885 |
| US-20240009169-A9 | PPARG Modulators for the Treatment of Osteoporosis | PPARG, PPARA, PPARD | ALDH1A1 4575/4885CYP4F2 2621/4885CYP4A11 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.